Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Dividend Re-investment (Deferred Annual Bonus Plan) |
| Instrument | Ordinary Shares of 25 pence each |
| Share Price | £16.285 |
| Total Volume | 1,305.26 shares |
| Transaction Date | July 14, 2016 |
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Mr. S A Hussain, President of Global Pharmaceuticals. This change resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan. No material changes to the company's financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of an executive share transaction.
Key Facts for Investor Verification
- The filing is a transaction notification for Mr. S A Hussain, not a financial earnings report.
- The transaction involved the re-investment of dividends into 1,305.26 shares at a price of £16.285 per share.
- The transaction occurred on July 14, 2016, under the 2009 Deferred Annual Bonus Plan.
- Company-wide financial performance data is not included in this specific filing.